Kornimate/medical-research-clean huggingface dataset:
hepatocellular carcinoma (hcc) transarterial chemoembolisation (tace) +axitinib

Conditions: Hepatocellular Carcinoma

Summary: the survival of subjects with unresectable hepatocellular carcinoma (hcc) receiving transarterial chemoembolization is improved with addition of axitinib.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed hcc (or fulfilling aasld criteria for hcc diagnosis in hbsag positive subjects with cirrhosis in case biopsy is not feasible) 2. disease must not be amenable to potentially curative surgery 3. without prior systemic nor transarterial treatment 4. prior surgery or local therapy is allowed but the target lesion must have not been previously treated 5. child-pugh stage a liver function 6. ecog performance 0-2 7. life expectancy longer than 12 weeks 8. at least one measurable treatment lesion according to modified recist criteria 9. adequate haematological, hepatic and renal function exclusion criteria: 1. contra-indications to tace treatment: * main portal vein thrombosis or occlusion * evidence of biliary obstruction * presence of extra-hepatic disease 2. diffuse-type hcc 3. major surgery \<4 weeks or radiation therapy \<2 weeks of starting the study treatment. 4. any form of prior transarterial therapy or systemic therapy for hcc. 5. current use or anticipated need for treatment with drugs that are known potent cyp3a4 inhibitors or cyp3a4 or cyp1a2 inducers. 6. requirement of anticoagulant therapy with oral vitamin k antagonists. low dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed. therapeutic use of low molecular weight heparin is allowed. 7. any haemorrhage or bleeding event of ctcae grade 3 or more within 4 week

Keywords: unresectable
steadysense -early detection of postoperative infections through continuous temperature measurement

Conditions: Body Temperature; Postoperative Infection; Pneumonia

Summary: the goal of this observational study is to review whether postoperative infections can be detected earlier by a continuous measurement of body temperature of patients compared to single daily measurements. within 25 weeks 100 patients, which underwent visceral surgery less than 48h ago, will be included. a patch (steadytemp ®) will be attached to participants, continuously measuring the body temperature. in addition infection parameters and medication of the participants will be documented.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study * age 18 years and above * visceral surgery procedure within the last two days * inpatient stay on the iciü (interdisciplinary surgical intensive care unit) or normal ward exclusion criteria: * allergy to the ingredients of skin patches * major psychiatric diseases including history of drug or alcohol abuse * chronic inflammatory disease in the medical history * predicted inpatient stay is less than 5 days * operational wound is too close to the patch adhesive site * the skin at the intended adhesive site of the patch is not intact * bmi \> 33
neurorealign therapy for cognitive rehabilitation in patients with stroke

Conditions: Stroke

Summary: the goal of this randomized controlled trial is to investigate the effects of neurorealign therapy on cognition in stroke survivors in the chronic stage (\>6 months). the study will include male and female participants aged 18-70 years. the main questions it aims to answer are: does neurorealign therapy improve cognition in stroke survivors compared to conventional physiotherapy? researchers will compare neurorealign therapy to conventional cognitive therapy to determine its effects on cognition. participants will: undergo neurorealign therapy or conventional cognitive therapy for 4 weeks. have their cognition evaluated using the montreal cognitive assessment (moca), mini-mental state examination (mmse), trail making test (tmt), stroop test, digit span test, and verbal fluency test (vft). complete outcome assessments at baseline and after the intervention (week 4).


Eligibility criteria:
inclusion criteria: * patients with ischemic or hemorrhagic stroke * have a stroke more than 6 months * age between 18 and 70 exclusion criteria: * patients with severe cognitive impairments * patients cannot walk independently
imaging of joint replacement complications by pet/ct

Conditions: Adverse Reactions to Metal Debris; Infection of Total Hip Joint Prosthesis; Mechanical Loosening of Prosthetic Joint

Summary: total hip replacement is the well-established surgical method for treatment of hip osteoarthritis and related diseases. the outcome of the procedure is commonly satisfactory and most patients will not need any revision surgery. however, the procedure has its complications, including (1) periprosthetic infection, (2) mechanical loosening caused by wear particles and (3) adverse reaction caused by metal ions released from metal-on-metal bearing surfaces. the unsolved clinical problem is related to the differential diagnosis of these conditions. the purpose of this prospective clinical study is to compare the efficacy of two techniques of pet/ct imaging in the differential diagnosis of these complications. positron emission tomography (pet)/computed tomography (ct) imaging, performed during a single day, will include the head-to-head comparison of 18f-fluoro-d-glucose (18f-fdg) pet/ct and 68gallium-citrate (68ga-citrate) pet/ct imaging.

(68ga) gallium citrate is a novel pet tracer aimed for detection of skeletal infections. it has not been previously applied to diagnose periprosthetic joint infections in arthroplasty patients. this exploratory prospective study, representing the first of its kind, examines the use of 68ga-citrate as a diagnostic tool of periprosthetic infections aside with 18f-fdg tracer as the standard reference. the first study group (n=10) will include total hip replacement patients without infection. the recruited patients should suffer from pain and/or functional impairment due to adverse reaction to metal debris (armd) caused by metal-on-metal bearings. the diagnosis of armd should be based on metal artifact reduction sequence magnetic resonance imaging (mars-mri). the patients will undergo the same-day comparison of the two pet/ct tracers. the second study group (n=10) will include total hip replacement patients with bacteriologically confirmed periprosthetic joint infection. the third group (n=10) will include patients with aseptic loosening of total hip prosthesis.

Eligibility criteria:
inclusion criteria: * adult patients with uncemented total hip replacement * american society of anesthesiology score i-iii * group 1: local symptoms and mri findings of the operated hip fulfilling the criteria of armd due to metal-on-metal bearings of the hip prosthesis, infection ruled out * group 2: bacteriologically verified periprosthetic infection of the hip prosthesis * group 3: local symptoms and radiographic findings of the hip prosthesis fulfilling the criteria of aseptic mechanical implant loosening, infection ruled out exclusion criteria: * any related condition of the index hip which requires immediate surgical intervention, such as a septic infection or a periprosthetic fracture * any systemic disorder or condition (asa iv) which makes the patient an unlikely candidate for revision surgery of the affected hip implant
analgesic effect of preoperative dexamethasone in gynecological laparotomies - a dose-ranging study

Conditions: Postoperative Pain; Postoperative Nausea and Vomiting; Fatigue

Summary: the objective of the study is to examine the effect of the addition of intravenous dexamethasone 1.5 hours prior to induction of anesthesia on the post-operative opioid consumption, pain scores, fatigue, and recovery in patients undergoing gynecological surgery with laparotomy under general anesthesia. this is a dose finding study with two different doses (0.1 mg/kg vs. 0.2 mg/kg) of dexamethasone to find out the optimal efficacious dose of dexamethasone with minimal side effects. dexamethasone has anti-inflammatory, immunomodulatory, and analgesic effects; and is superior to placebo in providing post-operative pain control, lower analgesic consumption, prevention of postoperative nausea and vomiting, lesser post-operative fatigue, and better recovery profile. no dose response study has been done. the investigators hypothesize that a higher dose of dexamethasone may have an incremental beneficial effect.


Eligibility criteria:
inclusion criteria: * patients must be non-lactating * 18-65 years of age * asa groups i-iii for elective total abdominal hysterectomy (with or without salpingo-oophorectomy or minor bladder repair)or myomectomy through a lower transverse or low midline incision under general anesthesia. incidental appendectomy and /or abdominal lipectomy were allowed as collateral surgical procedures if the same incision was used exclusion criteria: * emergent procedures * diagnosed malignancy * history of allergy to dexamethasone * allergy or contraindication to drugs used in study and anesthesia * patients with uncontrolled diabetes mellitus, recent history of gastrointestinal bleeding or ulceration within 30 days before the study) * patients who have taken drugs in the 12 hours preceding the surgery that could confound the analgesic response (specifically analgesics, neuroleptics, corticosteroids, nsaids) * patients who have been on long term oral steroid therapy * patients with bmi\>40 * serious organ disease/ dysfunction * chronic pain patients requiring \>30mg morphine per day or equivalent * severe psychiatric disease * drug addiction * pregnancy * language barrier * inability to cooperate with the use of the intravenous pca morphine pump

Keywords: elective total abdominal hysterectomy (with or without salpingo-oophorectomy or minor bladder repair) or myomectomy through a lower transverse or low midline incision under general anesthesia
valerian to improve sleep in patients with parkinson's disease

Conditions: Insomnia; Parkinson's Disease

Summary: the purpose of this trial is to test the short-term effectiveness of valerian, a medicinal herb, to improve sleep in patients with parkinson's disease (pd).

patients with pd have exceptionally poor sleep. sleep in patients with pd is characterized by excessive activity in surface electromyographic (emg) recordings from many different muscle groups. despite sleep disturbances, approximately 50% of patients experience a transient (1 to 3 hour) reduction in waking motor symptoms upon arising in the morning. this effect has been termed sleep benefit. this study will evaluate the effects of valerian, a medicinal herb, on the sleep of patients with pd. this is a 17 day study where participants will be evaluated by polysomnography on days one, two, three, sixteen and seventeen.. polysomnographic measurements will include customary variables such as total sleep time, sleep efficiency, and sleep latency, as well as emg measures of periodic and isolated muscle activity during sleep. participants will be required to keep a detailed sleep log of their self reported sleep characteristics across the entire 17 study nights. outcomes will include measures of both nocturnal sleep and waking motor function. assessments of motor function will be made the morning immediately following nights 3 and 17 in order to test for improvement related to improved sleep. on the morning following night 17, participants are provided with a one-week supply of valerian in an open label extension. participants are provided an additional sleep log for this week and asked to return the sleep log when they complete the open label phase.

Eligibility criteria:
inclusion criteria * idiopathic parkinson's disease * willing to undergo overnight, in-lab polysomnography * sufficient literacy to allow completion of sleep logs * stable doses and timing of all parkinsonian medications during the course of the trial exclusion criteria * dementia * parkinsonism secondary to toxic, infectious, or other medical conditions * history of stroke, cerebellar disease, or progressive supranuclear palsy * history of liver or renal disease * history of duodenal or bladder obstruction

Keywords: sleep
dry needling for myofascial pain syndrome

Conditions: Myofascial Pain Syndromes; Neck Pain

Summary: myofascial pain syndrome (mas) is defined as a regional painful syndrome characterized by pain and tenderness in a muscle group or a muscle, a taut band within the muscle, pain reflected by pressing, and the presence of trigger points. it causes localized muscle pain in the shoulder and neck. the frequency of mas is around 12% in the normal population, and its frequency increases in those with chronic diseases. it is more common in the 30-60 age range and in the female population. mechanical causes such as micro-macro trauma, nociceptive disorders, physical fatigue, psychological stress and genetic factors are blamed in its etiopathogenesis. painful myofascial trigger points may occur by pressing on all muscles in the body, although it is more common in the trazius muscle, especially in those who work at a desk, who are constantly in a certain position, and who are sedentary. myofascial trigger points are often detected by examination.

there is a difference between the pain, neck extension range of motion, neck functional status of 3 different dry needling methods used in routine treatment in patients with myofascial pain syndrome. the investigators set out by thinking which method is more appropriate to choose in our practice. when the investigators examined the literature, the investigators could not find a study comparing these methods. however, at the points where sham needling, lidocaine administration, ozone cost, kinesiotaping methods and dry needling are compared by using these methods separately, regardless of the method of dry needling, there is a significant improvement in functional status, pain score, attachments, improvement expenses in the range of motion. however, the investigators think that it will contribute to a study literature on the protection of these purposes more clearly.

Eligibility criteria:
inclusion criteria: * among the patients who applied to sultan 2. abdulhamid han hospital physical medicine and rehabilitation department and were diagnosed with myofascial pain syndrome * decided to receive dry needling treatment * between the ages of 18 and 65 * at least 1 painful myofascial trigger point in the m.trapezius, m.levator scapula muscles * patients with neck pain lasting less than 6 months exclusion criteria: * those with a history of cervical operation * those who have a history of shoulder operation * patients with radiculopathy as a result of the examination * those who have been injected into the determined area in the last 3 months * those diagnosed with fibromyalgia according to the 2018 fibromyalgia scale * those with cervical disc herniation in the mr imaging taken within the last 1 year * pregnant/pregnant women * those who are allergic to silver * those with a history of malignancy * those with positive red flags * those with known rheumatological disease * those who do not accept dry needling * those with cognitive impairment * those who have local infection in the application area

Keywords: dry needling neck pain myofascial pain syndromes
preventing smoking relapse after total joint replacement surgery

Conditions: Smoking; Smoking Cessation

Summary: hospitalization for elective knee or hip replacement surgery presents an outstanding opportunity to motivate people to quit smoking, because it provides an opportunity to encourage patients to remain smoke-free as they proactively quit to optimize their surgery outcomes. this study will conduct a comparative effectiveness trial of patients who quit smoking pre-operatively, comparing the current standard of care with a novel comprehensive relapse prevention intervention guided by marlatt's relapse prevention model.

the specific aims of this study are to evaluate the effectiveness and cost-effectiveness of the relapse prevention intervention and will: 1) compare the effectiveness of standard post-operative cessation treatment with a comprehensive relapse prevention intervention on smoking cessation outcomes; 2) conduct a comparative economic analysis to assess the value of the relapse prevention intervention for patients and the healthcare system; and 3) explore the impact of the interventions on surgical complications and readmissions.

Eligibility criteria:
inclusion criteria: patient participants * received preoperative smoking cessation counseling through orthopedic surgery quit smoking program * undergoing elective knee or hip arthroplasty surgery * have not smoked any cigarettes in the week prior to admission and carbon monoxide 4 ppm46,47 * have a cell phone (for text messaging) * provide informed consent in english caregiver participants: * age ≥ 18 years * be a caregiver of the patient participant * provide informed consent in english exclusion criteria: * patients will be excluded if they used smokeless tobacco or an electronic cigarette in the last 30 days.
single-centre, randomised, double-blind, placebo-controlled, four-way crossover clinical study to investigate safety and tolerability and pharmacokinetics of single doses of cm3.1-ac100 in patients with type 2 diabetes

Conditions: Type II Diabetes Mellitus

Summary: the primary objective of this study is to assess the safety and tolerability of the glucagon-like peptide-1 (glp-1) peptide analogue cm3.1-ac100 after single subcutaneous (sc) doses in patients with t2dm.


Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent prior to any study specific procedures 2. type 2 diabetes mellitus patient, diagnostically confirmed since at least 6 months 3. male or female patient aged 18 to 75 years at screening, both inclusive 4. bmi \>22 to ≤40 kg/m2 at screening exclusion criteria: 1. type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, eg cushings's syndrome and acromegaly 2. fasting c-peptide \< 500 pm at screening 3. acute gastrointestinal symptoms at the time of screening and/or day -1 4. any clinically relevant history or the presence of cardiovascular, bronchopulmonary, gastrointestinal or neurological diseases inclusive history of chronic pancreatitis or acute pancreatitis
spherical aberration on the optical of two different aspherical intraocular lenses

Conditions: Cataract

Summary: purpose: to compare the effect of spherical aberration on optical quality in eyes with two different aspherical intraocular lenses methods: in this prospective, randomized clinical trial 120 eyes of 60 patients underwent phacoemulsification. in patient's eyes an aberration-free aspherical iol (aspira-aa; human optics) or an aberration-correcting aspherical iol (tecnis zcb00; abott medical optics) were randomly implanted. three months after surgery visual acuity, contrast sensitivity, wavefront measurements with itrace as well as tilt and decentration measurements with visante anterior segment oct were performed.


Eligibility criteria:
inclusion criteria: * bilateral age-related cataract * potential postoperative visual acuity of 1.0 snellen * no relevant ocular pathology other than cataract * written informed consent to surgery and participation in the study exclusion criteria: * amblyopia, diabetic retinopathy, uveitis or other relevant ophthalmic diseases * optical media disturbances due to: corneal and vitreal opacity, pex * preceding ocular trauma or ocular surgery within 6 months * inability to cooperate * pregnancy (a pregnancy test will be performed preoperatively in women of reproductive age)
stimulation-evoked calcitonin gene-related peptide (cgrp) as biomarker of migraine

Conditions: Migraine

Summary: this study aims to improve the management migraine by providing a more profound understanding of the interactions of pain disinhibition on the brain stem level and calcitonin gene-related peptide as a main mediator in the generation of migraine headaches. for this purpose, this observational study investigates established neurophysiological and blood biomarkers parameters in association with the clinical phenotype.

the study's focus is the investigation of mechanisms that are directly related to the pain generation in migraine. in this context, the primary endpoint is an enhancement of trigeminal stimulation evoked calcitonin gene-related peptide (cgrp). the stimulation is normalized using an established protocol to elicit the nociceptive blink reflex, which is a brain stem reflex to study the trigemino-spinal system. we expect cgrp levels to rise more in patients affected by migraine as compared to controls, based on the observation that painful stimulation elicits migraine attacks. furthermore, baseline cgrp levels and their association with markers of brainstem excitability are probed.

Eligibility criteria:
inclusion criteria: * migraine according to ichd-3 criteria (cases) * no headaches or tension-type headache frequency \<1x/year (controls) exclusion criteria: * other chronic pain disorder
filgotinib alone and in combination with methotrexate (mtx) in adults with moderately to severely active rheumatoid arthritis who are naive to mtx therapy

Conditions: Rheumatoid Arthritis

Summary: the primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (mtx) versus mtx alone in adults with active rheumatoid arthritis (ra).


Eligibility criteria:
key inclusion criteria: * have a diagnosis of ra (2010 american college of rheumatology \[acr\]/european league against rheumatism \[eular\] criteria) and are acr functional class i-iii. * have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (sjc66)) and ≥ 6 tender joints (from a tender joint count based on 68 joints (tjc68)) at both screening and day 1. * limited or no prior treatment with mtx key exclusion criteria: * previous treatment with any janus kinase (jak) inhibitor * previous therapy for longer than 3 months with conventional synthetic disease modifying antirheumatic drugs (csdmards) other than mtx or hydroxychloroquine * use of any licensed or investigational biologic disease-modifying antirheumatic drugs (dmards) note: other protocol defined inclusion/exclusion criteria may apply.